Jamie Dananberg Sells 5,521 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) insider Jamie Dananberg sold 5,521 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $2.96, for a total value of $16,342.16. Following the transaction, the insider now owns 33,479 shares in the company, valued at $99,097.84. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Annexon Price Performance

ANNX opened at $2.81 on Friday. The stock’s 50 day simple moving average is $4.26 and its 200 day simple moving average is $5.55. The stock has a market cap of $299.52 million, a P/E ratio of -2.68 and a beta of 1.07. Annexon, Inc. has a 1-year low of $2.63 and a 1-year high of $8.40.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ANNX. Needham & Company LLC restated a “buy” rating and issued a $16.00 price target on shares of Annexon in a research note on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Annexon in a report on Tuesday, December 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Annexon currently has a consensus rating of “Buy” and an average price target of $15.80.

Institutional Trading of Annexon

Several large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets acquired a new position in shares of Annexon during the 4th quarter worth $59,000. CANADA LIFE ASSURANCE Co purchased a new position in Annexon during the 4th quarter valued at about $77,000. E Fund Management Co. Ltd. raised its position in Annexon by 36.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after acquiring an additional 4,086 shares during the last quarter. Forefront Analytics LLC lifted its holdings in shares of Annexon by 56.8% in the fourth quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock valued at $84,000 after purchasing an additional 5,950 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Annexon in the fourth quarter valued at about $98,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.